Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022010813 - ENHANCING IMMUNE RESPONSES THROUGH TARGETED ANTIGEN EXPRESSION

Publication Number WO/2022/010813
Publication Date 13.01.2022
International Application No. PCT/US2021/040392
International Filing Date 03.07.2021
IPC
A61K 47/69 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 48/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/86 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
A61K 47/62 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
Applicants
  • RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY [US]/[US]
  • PHAGENOVA BIO, INC. [US]/[US]
Inventors
  • PASQUALINI, Renata
  • ARAP, Wadih
  • LIBUTTI, Steven
  • MARKOSIAN, Christopher
  • STAQUICINI, Daniela
  • TANG, Fenny
  • SMITH, Tracey
  • YAO, Virginia J.
Agents
  • SILVA, Domingos J.
  • BROWNING, Elizabeth
  • CROTTY, Justin
  • DOYLE, Kathryn
  • LANDRY, Brian R.
  • LEICHT, Paul
  • O'BRIEN, Kevin
  • OSTROVSKY, Dennis
  • SIMPSON, Mark D.
  • YOUNG, Jacque
Priority Data
63/048,27906.07.2020US
63/161,13615.03.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ENHANCING IMMUNE RESPONSES THROUGH TARGETED ANTIGEN EXPRESSION
(FR) AMÉLIORATION DE RÉPONSES IMMUNITAIRES PAR EXPRESSION D'ANTIGÈNE CIBLÉE
Abstract
(EN) The present disclosure includes an immunogenic composition comprising an effective amount of a therapeutic engineered phage and a pharmaceutically acceptable carrier. In certain aspects, the disclosure includes a method of stimulating an immune response in a subject comprising administering to the subject a composition comprising an effective amount of a therapeutic engineered phage. In certain aspects, the disclosure includes a method for treating, ameliorating, and/or preventing a coronavirus infection in a subject comprising administering a composition comprising an effective amount of a therapeutic engineered phage.
(FR) La présente divulgation concerne une composition immunogène comprenant une quantité efficace d'un phage modifié thérapeutique et un vecteur pharmaceutiquement acceptable Selon certains aspects, la divulgation concerne une méthode de stimulation d'une réponse immunitaire chez un sujet, comprenant l'administration au sujet d'une composition comprenant une quantité efficace d'un phage modifié thérapeutique. Selon certains aspects, l'invention concerne une méthode de traitement, d'atténuation et/ou de prévention d'une infection à coronavirus chez un sujet, comprenant l'administration d'une composition comprenant une quantité efficace d'un phage modifié thérapeutique.
Latest bibliographic data on file with the International Bureau